课题基金 / 基金详情

PHASE I MULTIPLE DOSE STUDY OF OLTIPRAZ IN SMOKERS - WOR

PHASE I MULTIPLE DOSE STUDY OF OLTIPRAZ IN SMOKERS - WOR
奥替普拉在吸烟者中的 I 期多剂量研究 - WOR
批准号：
6157694
负责人：
Raymond C. Bergan
金额：
$42.23万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-09-30 至 2001-09-29
来源：
https://reporter.nih.gov/project-details/6157694
关键词：
adduct alveolar macrophages benzopyrenediol epoxide clinical research clinical trial phase I dosage drug screening /evaluation human subject oltipraz pharmacokinetics placebos respiratory epithelium smoking smoking cessation tobacco abuse

项目摘要

项目成果

Raymond C. Bergan的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The investigators will conduct a phase 1 clinical study of placebo, 200 mg and 400 mg Oltipraz administered to 20 current smokers per group for 12 weeks. Endpoints of dosimetry will include DNA and hemoglobin adducts of benzo(a)pyrene-7,8-diol-9,10-epoxide in bronchoalveolar macrophages from lavage and epithelial cells from biopsy, and blood lymphocytes and oral mucosa cells. Endpoints will also include measurements of oxidation status, phase II enzymes activities, and 4-aminobiphenyl adducts in bladder lining cells. Correlations will be made with GSTM1 genotype. Tolerability and toxicity will be assessed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preventing invasive prostate cancer
Therapeutically targeting cancer cell motility
  • 批准号：
    9206893
  • 项目类别：
  • 资助金额：
    $0.0万
  • 财政年份：
    2016
  • 负责人：
    Raymond C. Bergan
  • 依托单位：
    PORTLAND VA MEDICAL CENTER
Career Development Program
P-4: Modulation of Prostate CA Cell Motility by Chemopreventive Agt Genistein
海外基金